Collegium Pharma (COLL) Tops Q3 EPS by 4c

Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $1.61, $0.04 better than the analyst estimate of $1.57. Revenue for the quarter came in at $159.3 million versus the consensus estimate of $156.88 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• MIND Technology (MIND) Misses Q1 EPS by 5c